Swiss pharmaceutical company Novartis has secured the expanded US Food and Drug Administration (FDA) indication for Entresto, a Novartis therapy to treat patients diagnosed with guideline-defined heart failure.
The post Novartis secures expanded FDA indication label for Entresto appeared first on Pharmaceutical Business review.